Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope
Year: 2019
Type: review
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.13629
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: heart failure, type 2 diabetes, cardiovascular outcome trials, SGLT2 inhibitors, GLP-1 receptor agonists, dapagliflozin, saxagliptin, cardiovascular safety, major adverse cardiovascular events, HbA1c, dipeptidyl peptidase inhibitors, heart failure hospitalization, class effect, hyperglycemia
Open Access status: closed
OpenAlex ID: W2908065012
